## Inger SundstrĶm-Poromaa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3588391/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pregnancy and brain architecture: Associations with hormones, cognition and affect. Journal of Neuroendocrinology, 2022, 34, e13066.	1.2	9
2	There is no association between combined oral hormonal contraceptives and depression: a Swedish registerâ€based cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 917-925.	1.1	17
3	Prevalence and correlates of current suicidal ideation in women with premenstrual dysphoric disorder. BMC Women's Health, 2022, 22, 35.	0.8	13
4	Associations between capillary glucose during pregnancy and childhood growth to the age of five: a cohort study. Scientific Reports, 2022, 12, 1832.	1.6	2
5	White matter microstructure and volume correlates of premenstrual dysphoric disorder. Journal of Psychiatry and Neuroscience, 2022, 47, E67-E76.	1.4	6
6	Grey matter correlates of affective and somatic symptoms of premenstrual dysphoric disorder. Scientific Reports, 2022, 12, 5996.	1.6	5
7	Longitudinal assessment of inflammatory markers in the peripartum period by depressive symptom trajectory groups. Brain, Behavior, & Immunity - Health, 2022, 22, 100468.	1.3	3
8	Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial. American Journal of Psychiatry, 2021, 178, 256-265.	4.0	37
9	Neuroimaging the menstrual cycle: A multimodal systematic review. Frontiers in Neuroendocrinology, 2021, 60, 100878.	2.5	75
10	DNA methylation in cord blood in association with prenatal depressive symptoms. Clinical Epigenetics, 2021, 13, 78.	1.8	14
11	Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator. Neuropsychopharmacology, 2021, 46, 1460-1467.	2.8	16
12	Low- and Fully N-Glycosylated Gonadotropins Circulating in Women With Polycystic Ovary Syndrome. Journal of the Endocrine Society, 2021, 5, bvab080.	0.1	2
13	Peritoneal cancer index predicts severe complications after ovarian cancer surgery. European Journal of Surgical Oncology, 2021, 47, 2915-2924.	0.5	6
14	Significant increases of the amygdala between immediate and late postpartum: Pronounced effects within the superficial subregion. Journal of Neuroscience Research, 2021, 99, 2261-2270.	1.3	6
15	Associations Between Maternal Depression, Antidepressant Use During Pregnancy, and Adverse Pregnancy Outcomes. Obstetrics and Gynecology, 2021, 138, 633-646.	1.2	24
16	Contraceptives and Mood. Trends in Andrology and Sexual Medicine, 2021, , 45-56.	0.1	1
17	Postpartum Gray Matter Changes in the Auditory Cortex. Journal of Clinical Medicine, 2021, 10, 5616.	1.0	1
18	Inflammatory markers in women with postpartum depressive symptoms. Journal of Neuroscience Research, 2020, 98, 1309-1321.	1.3	43

#	Article	IF	CITATIONS
19	Impact of maternal central adiposity on infant anthropometry and perinatal morbidity: A systematic review. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2020, 8, 100117.	0.6	7
20	Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital <sup>®</sup> Gel) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled Study. Medical Devices: Evidence and Research, 2020, Volume 13, 339-347.	0.4	4
21	P.275 Severity of premenstrual dysphoric disorder symptoms correlates with grey matter volume and brain surface morphology. European Neuropsychopharmacology, 2020, 40, S158.	0.3	1
22	Association of maternal central adiposity measured by ultrasound in early mid pregnancy with infant birth size. Scientific Reports, 2020, 10, 19702.	1.6	6
23	Progesterone – Friend or foe?. Frontiers in Neuroendocrinology, 2020, 59, 100856.	2.5	70
24	Quantification of aromatase binding in the female human brain using [ <sup>11</sup> C]cetrozole positron emission tomography. Journal of Neuroscience Research, 2020, 98, 2208-2218.	1.3	5
25	Toward improved research on peripartum depression. Journal of Neuroscience Research, 2020, 98, 1253-1254.	1.3	1
26	SSRI use during pregnancy and risk for postpartum haemorrhage: a national registerâ€based cohort study in Sweden. BJOC: an International Journal of Obstetrics and Gynaecology, 2020, 127, 1366-1373.	1.1	15
27	Placental glucocorticoid receptors are not affected by maternal depression or SSRI treatment. Upsala Journal of Medical Sciences, 2020, 125, 30-36.	0.4	2
28	Risk factors for insulin resistance in midlife Singaporean women. Maturitas, 2020, 137, 50-56.	1.0	6
29	Neuroimaging premenstrual dysphoric disorder: A systematic and critical review. Frontiers in Neuroendocrinology, 2020, 57, 100838.	2.5	43
30	Neuroticism is associated with higher antenatal care utilization in obstetric lowâ€risk women. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 470-478.	1.3	2
31	Investigating the association between neuroticism and adverse obstetric and neonatal outcomes. Scientific Reports, 2019, 9, 15470.	1.6	1
32	Blood plasma metabolic profiling of pregnant women with antenatal depressive symptoms. Translational Psychiatry, 2019, 9, 204.	2.4	9
33	Maternal body mass index moderates antenatal depression effects on infant birthweight. Scientific Reports, 2019, 9, 6213.	1.6	12
34	Hypothalamic-pituitary-adrenal axis responsiveness, startle response, and sensorimotor gating in late pregnancy. Psychoneuroendocrinology, 2019, 106, 1-8.	1.3	7
35	Stress-related genetic polymorphisms in association with peripartum depression symptoms and stress hormones: A longitudinal population-based study. Psychoneuroendocrinology, 2019, 103, 296-305.	1.3	18
36	Pregnancy and neonatal complications in women with polycystic ovary syndrome in relation to second-trimester anti-Müllerian hormone levels. Reproductive BioMedicine Online, 2019, 39, 141-148.	1.1	13

#	Article	IF	CITATIONS
37	Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum. Scientific Reports, 2019, 9, 1863.	1.6	79
38	Cohort profile: the Biology, Affect, Stress, Imaging and Cognition (BASIC) study on perinatal depression in a population-based Swedish cohort. BMJ Open, 2019, 9, e031514.	0.8	30
39	Thromboinflammatory changes in plasma proteome of pregnant women with PCOS detected by quantitative label-free proteomics. Scientific Reports, 2019, 9, 17578.	1.6	9
40	Spring peaks and autumn troughs identified in peripheral inflammatory markers during the peripartum period. Scientific Reports, 2019, 9, 15328.	1.6	2
41	The effect of antenatal depression and antidepressant treatment on placental tissue: a protein-validated gene expression study. BMC Pregnancy and Childbirth, 2019, 19, 479.	0.9	14
42	Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term. Fertility and Sterility, 2019, 111, 588-596.e1.	0.5	42
43	Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use. European Journal of Contraception and Reproductive Health Care, 2018, 23, 45-51.	0.6	43
44	The Menstrual Cycle Influences Emotion but Has Limited Effect on Cognitive Function. Vitamins and Hormones, 2018, 107, 349-376.	0.7	46
45	Hormonal Cycle and Contraceptive Effects on Amygdala and Salience Resting-State Networks in Women with Previous Affective Side Effects on the Pill. Neuropsychopharmacology, 2018, 43, 555-563.	2.8	49
46	Potential Brain Age Reversal after Pregnancy: Younger Brains at 4–6†Weeks Postpartum. Neuroscience, 2018, 386, 309-314.	1.1	50
47	Negative Association Between Allopregnanolone and Cerebral Serotonin Transporter Binding in Healthy Women of Fertile Age. Frontiers in Psychology, 2018, 9, 2767.	1.1	12
48	Lower inflammatory markers in women with antenatal depression brings the M1/M2 balance into focus from a new direction. Psychoneuroendocrinology, 2017, 80, 15-25.	1.3	48
49	Inflammatory markers in late pregnancy in association with postpartum depression—A nested case-control study. Psychoneuroendocrinology, 2017, 79, 146-159.	1.3	51
50	Treatment of premenstrual dysphoric disorder with the GABA A receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial. Psychoneuroendocrinology, 2017, 80, 46-55.	1.3	93
51	Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle—A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology, 2017, 76, 135-143.	1.3	103
52	Sex differences in depression during pregnancy and the postpartum period. Journal of Neuroscience Research, 2017, 95, 719-730.	1.3	63
53	Maternal and female fetal testosterone levels are associated with maternal age and gestational weight gain. European Journal of Endocrinology, 2017, 177, 379-388.	1.9	52
54	Emotional anticipation after delivery – a longitudinal neuroimaging study of the postpartum period. Scientific Reports, 2017, 7, 114.	1.6	10

#	Article	IF	CITATIONS
55	Allopregnanolone levels and depressive symptoms during pregnancy in relation to single nucleotide polymorphisms in the allopregnanolone synthesis pathway. Hormones and Behavior, 2017, 94, 106-113.	1.0	36
56	Different patterns of attentional bias in antenatal and postpartum depression. Brain and Behavior, 2017, 7, e00844.	1.0	13
57	Neuroticism-related personality traits are associated with posttraumatic stress after abortion: findings from a Swedish multi-center cohort study. BMC Women's Health, 2017, 17, 96.	0.8	9
58	MID-PREGNANCY CORTICOTROPIN-RELEASING HORMONE LEVELS IN ASSOCIATION WITH POSTPARTUM DEPRESSIVE SYMPTOMS. Depression and Anxiety, 2016, 33, 1023-1030.	2.0	23
59	Suicides during pregnancy and 1 year postpartum in Sweden, 1980–2007. British Journal of Psychiatry, 2016, 208, 462-469.	1.7	103
60	Should we individualize lipid profiling in women with polycystic ovary syndrome?. Human Reproduction, 2016, 31, 2791-2795.	0.4	9
61	Tandem mass spectrometry determined maternal cortisone to cortisol ratio and psychiatric morbidity during pregnancyâ~'interaction with birth weight. Psychoneuroendocrinology, 2016, 69, 142-149.	1.3	23
62	Sleep duration, depression, and oxytocinergic genotype influence prepulse inhibition of the startle reflex in postpartum women. European Neuropsychopharmacology, 2016, 26, 767-776.	0.3	30
63	The effect of combined hormonal contraceptives use on brain reactivity during response inhibition. European Journal of Contraception and Reproductive Health Care, 2016, 21, 150-157.	0.6	26
64	The Effect of Antenatal Depression and Selective Serotonin Reuptake Inhibitor Treatment on Nerve Growth Factor Signaling in Human Placenta. PLoS ONE, 2015, 10, e0116459.	1.1	23
65	Personality and risk for postpartum depressive symptoms. Archives of Women's Mental Health, 2015, 18, 539-546.	1.2	64
66	Gene Expression in Placentas From Nondiabetic Women Giving Birth to Large for Gestational Age Infants. Reproductive Sciences, 2015, 22, 1281-1288.	1.1	13
67	Treatment with serotonin reuptake inhibitors during pregnancy is associated with elevated corticotropin-releasing hormone levels. Psychoneuroendocrinology, 2015, 58, 104-113.	1.3	29
68	Supraphysiological hormonal status, anxiety disorders, and COMT Val/Val genotype are associated with reduced sensorimotor gating in women. Psychoneuroendocrinology, 2015, 60, 217-223.	1.3	17
69	Neuroimaging the Menstrual Cycle and Premenstrual Dysphoric Disorder. Current Psychiatry Reports, 2015, 17, 77.	2.1	54
70	Antenatal depression and antidepressants during pregnancy: Unraveling the complex interactions for the offspring. European Journal of Pharmacology, 2015, 753, 257-262.	1.7	25
71	Emotion Reactivity Is Increased 4-6 Weeks Postpartum in Healthy Women: A Longitudinal fMRI Study. PLoS ONE, 2015, 10, e0128964.	1.1	45
72	Prenatal and Postpartum Evening Salivary Cortisol Levels in Association with Peripartum Depressive Symptoms. PLoS ONE, 2015, 10, e0135471.	1.1	69

#	Article	IF	CITATIONS
73	Periodic Limb Movements Are Associated with Vasomotor Symptoms. Journal of Clinical Sleep Medicine, 2014, 10, 15-20.	1.4	7
74	Emotional fronto ingulate cortex activation and brain derived neurotrophic factor polymorphism in premenstrual dysphoric disorder. Human Brain Mapping, 2014, 35, 4450-4458.	1.9	52
75	Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors. Menopause, 2014, 21, 383-390.	0.8	16
76	Targeted Thyroid Testing During Pregnancy in Clinical Practice. Obstetrics and Gynecology, 2014, 124, 10-15.	1.2	23
77	Physiological Correlates of Premenstrual Dysphoric Disorder (PMDD). Current Topics in Behavioral Neurosciences, 2014, 21, 229-243.	0.8	9
78	Association between trefoil factor 3 gene variants and idiopathic recurrent spontaneous abortion. Reproductive BioMedicine Online, 2014, 29, 737-744.	1.1	5
79	Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: A systematic review. Psychoneuroendocrinology, 2014, 50, 28-52.	1.3	265
80	Social stimulation and corticolimbic reactivity in premenstrual dysphoric disorder: a preliminary study. Biology of Mood & Anxiety Disorders, 2014, 4, 3.	4.7	33
81	The effects of antenatal depression and antidepressant treatment on placental gene expression. Frontiers in Cellular Neuroscience, 2014, 8, 465.	1.8	27
82	ISPMD consensus on the management of premenstrual disorders. Archives of Women's Mental Health, 2013, 16, 279-291.	1.2	162
83	Clinical subtypes of core premenstrual disorders: a Delphi survey. Archives of Women's Mental Health, 2013, 16, 197-201.	1.2	8
84	Allopregnanolone serum concentrations and diurnal cortisol secretion in women with premenstrual dysphoric disorder. Archives of Women's Mental Health, 2013, 16, 131-137.	1.2	25
85	Histidineâ€rich glycoprotein gene polymorphism in patients with recurrent miscarriage. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 974-977.	1.3	11
86	Cortisol awakening response in late pregnancy in women with previous or ongoing depression. Psychoneuroendocrinology, 2013, 38, 3150-3154.	1.3	51
87	Posttraumatic stress among women after induced abortion: a Swedish multi-centre cohort study. BMC Women's Health, 2013, 13, 52.	0.8	21
88	Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill—A double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive. Psychoneuroendocrinology, 2013, 38, 1133-1144.	1.3	118
89	Prefrontal activity during response inhibition decreases over time in the postpartum period. Behavioural Brain Research, 2013, 241, 132-138.	1.2	27
90	Thyroid function tests at delivery and risk for postpartum depressive symptoms. Psychoneuroendocrinology, 2013, 38, 1007-1013.	1.3	35

#	Article	IF	CITATIONS
91	Premenstrual dysphoric disorder and prefrontal reactivity during anticipation of emotional stimuli. European Neuropsychopharmacology, 2013, 23, 1474-1483.	0.3	47
92	Premenstrual syndrome and dysphoric disorder as risk factors for postpartum depression. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 178-184.	1.3	35
93	Influence of catechol-O-methyltransferase Val158Met polymorphism on startle response in the presence of high estradiol levels. European Neuropsychopharmacology, 2013, 23, 629-635.	0.3	11
94	Thyroid Testing and Management of Hypothyroidism During Pregnancy: A Population-based Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2687-2692.	1.8	34
95	The prevalence of posttraumatic stress among women requesting induced abortion. European Journal of Contraception and Reproductive Health Care, 2013, 18, 480-488.	0.6	15
96	Adipocytokines levels at delivery, functional variation of TFAP2Î <sup>2</sup> , and maternal and neonatal anthropometric parameters. Obesity, 2013, 21, 2130-2137.	1.5	6
97	Socioeconomic characteristics, housing conditions and criminal offences among women with cervical neoplasia. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 888-894.	1.3	1
98	The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring. Frontiers in Cellular Neuroscience, 2013, 7, 73.	1.8	93
99	Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause, 2013, 20, 162-168.	0.8	132
100	The A118G Single-Nucleotide Polymorphism of Human µ-Opioid Receptor Gene and Use of Labor Analgesia. Reproductive Sciences, 2012, 19, 962-967.	1.1	13
101	Biological Aspects of Postpartum Depression. Women's Health, 2012, 8, 659-672.	0.7	112
102	Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder. Hormones and Behavior, 2012, 62, 400-406.	1.0	96
103	The effect of premenstrual dysphoric disorder and menstrual cycle phase on brain activity during response inhibition. Journal of Affective Disorders, 2012, 142, 347-350.	2.0	57
104	Phosphodiesterase 8B gene polymorphism in women with recurrent miscarriage: A retrospective case control study. BMC Medical Genetics, 2012, 13, 121.	2.1	7
105	Women with acute intermittent porphyria have a defect in 5αâ€steroid production during the menstrual cycle. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1445-1452.	1.3	7
106	Prediction of Preeclampsia by Combining Serum Histidine-Rich Glycoprotein and Uterine Artery Doppler. American Journal of Hypertension, 2012, 25, 1305-10.	1.0	12
107	Decreased startle modulation during anticipation in the postpartum period in comparison to late pregnancy. Archives of Women's Mental Health, 2012, 15, 87-94.	1.2	15
108	Adverse mood symptoms with oral contraceptives. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 420-427.	1.3	88

#	Article	IF	CITATIONS
109	Ultrasonographic findings in spontaneous miscarriage: relation to euploidy and aneuploidy. Fertility and Sterility, 2011, 95, 221-224.	0.5	12
110	Androgen levels, insulin sensitivity, and early insulin response in women with polycystic ovary syndrome: a long-term follow-up study. Fertility and Sterility, 2011, 95, 1146-1148.	0.5	14
111	Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertility and Sterility, 2011, 96, 1271-1274.	0.5	45
112	Postpartum depression symptoms. Psychiatric Genetics, 2011, 21, 19-28.	0.6	58
113	Prevalence of violence exposure in women with premenstrual dysphoric disorder in comparison with other gynecological patients and asymptomatic controls. Acta Obstetricia Et Gynecologica Scandinavica, 2011, 90, 746-752.	1.3	12
114	Patients with premenstrual dysphoric disorder have increased startle modulation during anticipation in the late luteal phase period in comparison to control subjects. Psychoneuroendocrinology, 2011, 36, 1184-1192.	1.3	24
115	Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. American Journal of Obstetrics and Gynecology, 2011, 204, 26.e1-26.e7.	0.7	66
116	Seasonality patterns in postpartum depression. American Journal of Obstetrics and Gynecology, 2011, 204, 413.e1-413.e6.	0.7	31
117	Newborn gender as a predictor of postpartum mood disturbances in a sample of Swedish women. Archives of Women's Mental Health, 2011, 14, 195-201.	1.2	29
118	Postpartum depressive symptoms and the BDNF Val66Met functional polymorphism: effect of season of delivery. Archives of Women's Mental Health, 2011, 14, 453-463.	1.2	47
119	Allopregnanolone, a GABA <sub>A</sub> receptor agonist, decreases gonadotropin levels in women. A preliminary study. Gynecological Endocrinology, 2011, 27, 1087-1093.	0.7	14
120	Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17Î <sup>2</sup> -oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. European Journal of Contraception and Reproductive Health Care, 2011, 16, 430-443	0.6	88
121	No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls. Human Reproduction, 2011, 26, 1478-1485.	0.4	48
122	Patients with polycystic ovary syndrome have lower levels of IgM anti-phosphorylcholine antibodies than healthy women. Gynecological Endocrinology, 2011, 27, 486-490.	0.7	6
123	Sympathetic reactivity in late pregnancy is related to labour onset in women. Stress, 2011, 14, 627-633.	0.8	12
124	A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause, 2010, 17, 72-79.	0.8	27
125	Neuroticism-related personality traits are related to symptom severity in patients with premenstrual dysphoric disorder and to the serotonin transporter gene-linked polymorphism 5-HTTPLPR. Archives of Women's Mental Health, 2010, 13, 417-423.	1.2	46
126	Lower levels of prepulse inhibition in luteal phase cycling women in comparison with postmenopausal women. Psychoneuroendocrinology, 2010, 35, 422-429.	1.3	16

#	Article	IF	CITATIONS
127	Different SNP Combinations in the GCH1 Gene and Use of Labor Analgesia. Molecular Pain, 2010, 6, 1744-8069-6-41.	1.0	14
128	Healthâ€related quality of life and restless legs syndrome among women in Sweden. Psychiatry and Clinical Neurosciences, 2010, 64, 574-579.	1.0	19
129	Plasma Levels of β-Endorphin During Pregnancy and Use of Labor Analgesia. Reproductive Sciences, 2010, 17, 742-747.	1.1	15
130	Down-regulation of progesterone receptor membrane component 1 (PGRMC1) in peripheral nucleated blood cells associated with premature ovarian failure (POF) and polycystic ovary syndrome (PCOS). Reproductive Biology and Endocrinology, 2010, 8, 58.	1.4	42
131	Personality traits associated with depressive and anxiety disorders in infertile women and men undergoing in vitro fertilization treatment. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 27-34.	1.3	34
132	Risk factors for psychiatric disorders in infertile women and men undergoing in vitro fertilization treatment. Fertility and Sterility, 2010, 93, 1088-1096.	0.5	72
133	Endothelial function in patients with polycystic ovary syndrome: a long-term follow-up study. Fertility and Sterility, 2010, 94, 2654-2658.	0.5	7
134	Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecological Endocrinology, 2010, 26, 743-748.	0.7	17
135	Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacology Biochemistry and Behavior, 2009, 92, 608-613.	1.3	27
136	Risk of postpartum depression in association with serum leptin and interleukin-6 levels at delivery: A nested case–control study within the UPPSAT cohort. Psychoneuroendocrinology, 2009, 34, 1329-1337.	1.3	57
137	Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. American Journal of Obstetrics and Gynecology, 2009, 201, 139.e1-139.e8.	0.7	62
138	Prevalence of psychiatric disorders and premenstrual dysphoric symptoms in patients with experience of adverse mood during treatment with combined oral contraceptives. Contraception, 2009, 79, 50-55.	0.8	47
139	Allopregnanolone impairs episodic memory in healthy women. Psychopharmacology, 2008, 199, 161-168.	1.5	61
140	Measurement of direct ethanol metabolites suggests higher rate of alcohol use among pregnant women than found with the AUDIT—a pilot study in a population-based sample of Swedish women. American Journal of Obstetrics and Gynecology, 2008, 198, 407.e1-407.e5.	0.7	86
141	Action of Progesterone and Progesterone Metabolites in Menstrualâ€Cycle–Related Disorders. Headache, 2008, 48, S90.	1.8	2
142	Lower levels of prepulse inhibition of startle response in pregnant women compared to postpartum women. Psychoneuroendocrinology, 2008, 33, 100-107.	1.3	26
143	Patients with adverse mood effects from combined oral contraceptives have lower levels of prepulse inhibition than healthy controls. Psychoneuroendocrinology, 2008, 33, 487-496.	1.3	18
144	Prevalence of symptoms associated with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 2008, 102, 39-43.	1.0	51

#	Article	IF	CITATIONS
145	Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility, 2008, 89, 1221-1228.	0.5	44
146	Adverse mood effects of combined oral contraceptives in relation to personality traits. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 141, 127-130.	0.5	21
147	Restless legs syndrome among women: prevalence, co-morbidity and possible relationship to menopause. Climacteric, 2008, 11, 422-428.	1.1	105
148	Patients with Premenstrual Dysphoric Disorder have Increased Startle Response Across both Cycle Phases and Lower Levels of Prepulse Inhibition During the Late Luteal Phase of the Menstrual Cycle. Neuropsychopharmacology, 2008, 33, 2283-2290.	2.8	57
149	Neuroactive Steroids: Effects on Cognitive Functions. , 2008, , 103-121.		1
150	Neuroactive Steroids in Brain and Relevance to Mood. , 2008, , 423-433.		0
151	Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome. Gynecological Endocrinology, 2007, 23, 257-266.	0.7	49
152	Sulfonation and Sialylation of Gonadotropins in Women during the Menstrual Cycle, after Menopause, and with Polycystic Ovarian Syndrome and in Men. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4410-4417.	1.8	53
153	Increased cortisol responsivity to adrenocorticotropic hormone and low plasma levels of interleukin-1 receptor antagonist in women with functional hypothalamic amenorrhea. Fertility and Sterility, 2007, 87, 136-142.	0.5	14
154	Allopregnanolone serum concentrations and neurosteroid sensitivity during withdrawal from postmenopausal hormone therapy. Gynecological Endocrinology, 2007, 23, 590-596.	0.7	1
155	Patients with psychiatric disorders in gynecologic practice—a three year follow-up. Journal of Psychosomatic Obstetrics and Gynaecology, 2006, 27, 17-22.	1.1	7
156	Psychophysically Determined Thresholds for Thermal Perception and Pain Perception in Healthy Women Across the Menstrual Cycle. Clinical Journal of Pain, 2006, 22, 610-616.	0.8	31
157	No difference in length of hospital stay between laparoscopic and abdominal supravaginal hysterectomy – a preliminary study. Acta Obstetricia Et Gynecologica Scandinavica, 2006, 85, 682-687.	1.3	18
158	Depression and anxiety during pregnancy and six months postpartum: a followâ€up study. Acta Obstetricia Et Gynecologica Scandinavica, 2006, 85, 937-944.	1.3	264
159	Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology, 2006, 186, 414-424.	1.5	105
160	Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders. Psychopharmacology, 2006, 186, 388-401.	1.5	42
161	Allopregnanolone concentration and moodâ $\in$ "a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology, 2006, 187, 209-221.	1.5	65
162	Adverse mood effects during postmenopausal hormone treatment in relation to personality traits. Climacteric, 2006, 9, 290-297.	1.1	11

#	Article	IF	CITATIONS
163	Estradiol and the addition of progesterone increase the sensitivity to a neurosteroid in postmenopausal women. Psychoneuroendocrinology, 2005, 30, 38-50.	1.3	22
164	Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology, 2005, 30, 212-224.	1.3	80
165	The effect of a low dose of alcohol on allopregnanolone serum concentrations across the menstrual cycle in women with severe premenstrual syndrome and controls. Psychoneuroendocrinology, 2005, 30, 892-901.	1.3	31
166	Allopregnanolone and pregnanolone are produced by the human corpus luteum. Molecular and Cellular Endocrinology, 2005, 239, 37-44.	1.6	53
167	Postoperative infections and antibiotic prophylaxis for hysterectomy in Sweden: a study by the Swedish National Register for Gynecologic Surgery. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 1202-1207.	1.3	40
168	No difference in responsiveness to a low dose of alcohol between healthy women and men. Pharmacology Biochemistry and Behavior, 2004, 78, 603-610.	1.3	13
169	Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding. Psychoneuroendocrinology, 2004, 29, 757-766.	1.3	41
170	Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder. Psychoneuroendocrinology, 2004, 29, 767-777.	1.3	55
171	Neonatal Outcome following Maternal Antenatal Depression and Anxiety: A Population-based Study. American Journal of Epidemiology, 2004, 159, 872-881.	1.6	240
172	Implications of Antenatal Depression and Anxiety for Obstetric Outcome. Obstetrics and Gynecology, 2004, 104, 467-476.	1.2	267
173	Pathogenesis in Menstrual Cycle-Linked CNS Disorders. Annals of the New York Academy of Sciences, 2003, 1007, 42-53.	1.8	121
174	Point prevalence of psychiatric disorders during the second trimester of pregnancy: A population-based study. American Journal of Obstetrics and Gynecology, 2003, 189, 148-154.	0.7	359
175	Progesterone effects during sequential hormone replacement therapy. European Journal of Endocrinology, 2003, 148, 571-577.	1.9	50
176	Increase of Estrogen Dose Deteriorates Mood during Progestin Phase in Sequential Hormonal Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2026-2030.	1.8	58
177	Hormonally regulated α4β2δ GABAA receptors are a target for alcohol. Nature Neuroscience, 2002, 5, 721-722.	7.1	312
178	Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin2a receptor binding. Obstetrics and Gynecology, 2001, 98, 450-457.	1.2	6
179	Sensitivity to a Neurosteroid Is Increased during Addition of Progestagen to Postmenopausal Hormone Replacement Therapy. Neuroendocrinology, 2001, 73, 397-407.	1.2	12
180	Clinical and pregnancy outcome following ectopic pregnancy; a prospective study comparing expectancy, surgery and systemic methotrexate treatment. Acta Obstetricia Et Gynecologica Scandinavica, 2001, 80, 744-749.	1.3	31

#	Article	IF	CITATIONS
181	Patients with psychiatric disorders in gynecologic practice. American Journal of Obstetrics and Gynecology, 2001, 185, 396-402.	0.7	40
182	Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology, 2001, 26, 551-564.	1.3	20
183	Clinical and pregnancy outcome following ectopic pregnancy; a prospective study comparing expectancy, surgery and systemic methotrexate treatment. Acta Obstetricia Et Gynecologica Scandinavica, 2001, 80, 744-749.	1.3	1
184	Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. Journal of Psychosomatic Obstetrics and Gynaecology, 2000, 21, 205-211.	1.1	37